Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Non-steroidal Anti-inflammatory Drugs	317.24M
Non-steroidal Anti-inflammatory Drugs Growth	-40.69%
Cardiovascular Drugs	63.49M
Cardiovascular Drugs Growth	1.10%
Anti-tumor Drugs	23.62M
Anti-tumor Drugs Growth	-14.33%
Other	41.51M
Other Growth	9.94%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
China	236.99M
China Growth	-42.30%
Overseas	208.87M
Overseas Growth	-17.20%